Pharmahungary GroupPharmahungary Group (PH) developed miRNAtarget, a miRNA discovery software tool based on miRNA-mRNA molecular networks. PH holds patent families on 4 cardio-protective microRNAs families (protectomiRs) and seeks for co-development partners and/or early stage investors. PH also offers its miRNA discovery and development service platform that includes efficacy testing from in vitro to large animal models in various therapeutic areas.
Tag Archive for: miRNA
Abivax SAIn a watershed moment for both patients and investors, shares in Abivax (Euronext Paris: ABVX / Nasdaq: ABVX) skyrocketed by a staggering 500% following the announcement of positive Phase 3 results from its pivotal ABTECT induction trials investigating obefazimod, a first-in-class oral miR-124 enhancer, for moderate to severely active ulcerative colitis. Abivax cashes in with a US$400m public offering following suite.
Laverock TherapeuticsBritish targeted gene silencing specialist Laverock Therapeutics Ltd has expanded its seed funding to £20m by a new financing round led by xx and xx. The company said it will use the funds to…l
uniqure NVAmsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease.
Italian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.